Incidental Detection of Glioblastoma Multiforme With PSMA Uptake on Initial Prostate Cancer Staging.

Clin Nucl MedMar 31, 2026 (epub)

Mohammad Ahmadi, Amin Saber Tanha, Haniye Elahifard et al.

✦ AI-curated · Sources linked

Case in brief

A 75-year-old man with prostate adenocarcinoma underwent 99mTc-PSMA imaging for initial staging. The scan showed increased uptake in the skull; SPECT/CT localized a hypodense lesion to the brain parenchyma. He had recently developed left-sided hemiparesis. MRI and surgical pathology established glioblastoma multiforme in the PSMA-avid lesion, rather than a prostate cancer metastasis.

What made this case unusual

The intracranial glioblastoma showed PSMA uptake on prostate cancer staging imaging, creating a potential pitfall in interpreting an atypical avid lesion as metastatic disease.

Diagnostic / clinical pearl

PSMA-avid lesions outside the expected pattern of prostate cancer spread warrant anatomical correlation and evaluation; in this case, SPECT/CT, MRI, and pathology identified a primary brain tumour.

Why it matters

The authors note that PSMA uptake in glioblastoma may offer a potential target for theranostic approaches.

Source

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.